Top Industry Leaders in the Chinese Fibromyalgia Market
Latest Chinese Fibromyalgia Companies Update:
Eli Lilly China launched a campaign to raise awareness of fibromyalgia, featuring educational materials and patient testimonials. (Jan 2024)
Pfizer China partnered with leading hospitals to offer free fibromyalgia screening workshops for healthcare professionals. (Dec 2023)
The Chinese Medical Association released updated guidelines for fibromyalgia diagnosis and management, promoting standardized practices. (Nov 2023)
GenScript (China) introduced a new diagnostic kit for fibromyalgia, aimed at improving early detection and treatment initiation. (Jan 2024)
Yuyue Medical (China) received regulatory approval for its transcutaneous electrical nerve stimulation (TENS) device for fibromyalgia pain management. (Dec 2023)
InnoPharma Holdings (China) announced plans to launch a clinical trial for its novel non-opioid drug candidate for fibromyalgia treatment. (Nov 2023)
List of Chinese Fibromyalgia Key companies in the market
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Roche
- Astellas Pharma
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- SANOFI
- Bayer AG
- AbbVie
- ALLERGAN
- Boehringer Ingelheim
- Cephalon, Inc.
- Vertical Pharmaceuticals
- Sunovion Pharms Inc
- Jazz Pharmaceuticals
- ABBOTT
- NOVARTIS